Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: A randomised clinical trial

Lancet

Volumn 360, Issue 9332, 2002, Pages 528-534

  Benator, Debra ^a   Bhattacharya, Mondira ^a   Bozeman, Lorna ^a   Burman, William ^a   Catanzaro, Antonino ^a   Chaisson, Richard ^a   Gordin, Fred ^a   Horsburgh, C Robert ^a,a   Horton, James ^a   Khan, Awal ^a   Lahart, Christopher ^a   Metchock, Beverly ^a   Pachucki, Constance ^a   Stanton, Llewellyn ^a   Vernon, Andrew ^a   Villarino, M Elsa ^a   Yong, Cheng Wang ^a   Weiner, Marc ^a   Weis, Stephen ^a  

^a Division of Tuberculosis Elimination   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN; RIFAPENTINE;

ADULT; ARTICLE; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; ETHNIC GROUP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LIVER TOXICITY; LUNG CAVITATION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; NONBIOLOGICAL MODEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPUTUM CULTURE; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; UNDERWEIGHT; UNITED STATES;

EID: 0037125569     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)09742-8     Document Type: Article

References (33)

1. Fox W., Ellard G.A., Mitchison D.A. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 3:1999;S231-S279.
2. Combs D.L., O'Brien R.J., Geiter L.J. USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability. Ann Intern Med. 112:1990;397-406.
3. Weis S.E., Slocum P.C., Blais F.X., et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 330:1994;1179-1184.
4. Cohn D.L., Catlin B.J., Peterson K.L., Judson F.N., Sbarbaro J.A. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis: a twice-weekly, directly observed, and cost-effective regimen. Ann Intern Med. 112:1990;407-415.
5. Singapore Tuberculosis Service/British Medical Research Council. Controlled trial of intermittent regimens of rifampin plus isoniazid for pulmonary tuberculosis in Singapore: The results up to 30 months. Am Rev Respir Dis 1977; 116: 807-20.
6. Dickinson J.M., Mitchison D.A. In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis. Tubercle. 68:1987;113-118.
7. Ji B., Truffot-Pernot C., LaCroix C., et al. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis. 148:1993;1541-1546.
8. Keung A.C., Eller M.G., McKenzie K.A., Weir S.J. Single and multiple dose pharmacokinetics of rifapentine in man: Part II. Int J Tuberc Lung Dis. 3:1999;437-444.
9. Acocella G., Pagani V., Marchetti M., Baroni G.C., Nicolis F.B. Kinetic studies on rifampicin: serum concentration analysis in subjects treated with different oral doses over a period of two weeks. Chemotherapy. 16:1971;356-370.
10. Bass J.B.J., Farer L.S., Hopewell P.C., et al. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med. 149:1994;1359-1374.
11. Vernon A., Burman W., Benator D., Khan A., Bozeman L. Relapse with rifamycin mono-resistant tuberculosis in HIV-infected patients treated with supervised once-weekly rifapentine and isoniazid. Lancet. 353:1999;1843-1847.
12. Kent PT, Kubica GP. Public Health Mycobacteriology: A Guide for the Level III Laboratory. Atlanta, GA: Centers for Disease Control and Prevention, US Public Health Service, 1985.
13. Cave M.D., Eisenach K.D., Templeton G., et al. Stability of DNA fingerprint pattern produced with IS6110 in strains of Mycobacterium tuberculosis. J Clin Microbiol. 32:1994;262-266.
14. Chaves F., Yang Z., el Hajj H., et al. Usefulness of the secondary probe pTBN12 in DNA fingerprinting of Mycobacterium tuberculosis. J Clin Microbiol. 34:1996;1118-1123.
15. Burman W.J., Stone B.L., Reves R.R., et al. The incidence of false-positive cultures of Mycobacterium tuberculosis. Am J Respir Crit Care Med. 155:1997;321-326.
16. 1983 metropolitan height and weight tables. Stat Bull Metrop Life Found 1983; 64: 3-9.
17. O'Brien P.C., Fleming T.C. A multiple testing procedure for clinical trials. Biometrics. 35:1979;549-556.
18. Aber V.R., Nunn A.J. Factors affecting relapse following short-course chemotherapy. Bull Int Union Against Tuberculosis. 53:1978;260-264.
19. Zierski M., Bek E., Long M.W., Snider D.E. Jr. Short-course (6 month) cooperative tuberculosis study in Poland: results 18 months after completion of treatment. Am Rev Respir Dis. 122:1980;879-889.
20. Mitchison D.A. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis. 147:1993;1062-1063.
21. Centers for Disease Control and Prevention. Reported Tuberculosis in the United States, 1998-99. Atlanta: CDC, 1999.
22. Tam C.M., Chan S.L., Lam C.W., et al. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis: initial report. Am J Respir Crit Care Med. 157:1998;1726-1733.
23. Anon. Package Insert Rifapentine (Priftin®). Kansas City: Hoechst Marion Roussel, 1998.
24. Tam C.M., Chan S.L., Lam C.W., Dickinson J.M., Mitchison D.A. Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong. Int J Tuberc Lung Dis. 1:1997;411-416.
25. Weiner M., Khan A., Benator D., Peloquin C., Burman W. Low isoniazid (INH) levels are associated with TB treatment failure/relapse with once-weekly rifapentine and INH. Am J Respir Crit Care Med. 163:2001;A498. (abstr).
26. Mitchison D.A. Development of rifapentine: the way ahead. Int J Tuberc Lung Dis. 2:1998;612-615.
27. Heifets L.B., Lindhom-Levy P., Flory M.A. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. Am Rev Respir Dis. 141:1990;626-630.
28. Peloquin C.A., Namdar R., Singleton M.D., Nix D.E. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest. 115:1999;12-18.
29. Reith K., Keung A., Toren P., Cheng L., Eller M., Weir S. Disposition and metabolism of 14C-rifapentine in healthy volunteers. Drug Metab Dispos. 26:1998;732-738.
30. Boman G., Ringberger V.A. Binding of rifampicin by human plasma proteins. Eur J Clin Pharmacol. 7:1974;369-373.
31. the Tuberculosis Trials Consortium, Bock N.N., Conwell D.S., Pachucki C.T., Sterling T.R., Wang Y.C. Tolerability of once-weekly rifapentine 900 mg plus INH vs once-weekly rifapentine 600 mg plus INH during continuation phase treatment of pan-susceptible tuberculosis in HIV-negative adults. Am J Respir Crit Care Med. 165:2002;1526-1530.
32. Taylor Z., Qualls N., Vernon A., Villarino E., O'Brien R. A prevention effectiveness study of rifapentine in the continuation phase of therapy for active pulmonary tuberculosis. Am J Respir Crit Care Med. 161:2000;A524. (abstr).
33. Hong Kong Chest Service, Tuberculosis Research Centre Madras, and British Medical Research Council. A controlled clinical comparison of 6 and 8 months of antituberculosis chemotherapy in the treatment of patients with silicotuberculosis in Hong Kong. Am Rev Respir Dis 1991; 143: 262-67.